The role of 5-aminolevulinic acid in spinal tumor surgery: a review

John V. Wainwright1 · Toshiki Endo2 · Jared B. Cooper1 · Teiji Tominaga2 · Meic H. Schmidt1

Received: 27 June 2018 / Accepted: 17 December 2018 / Published online: 29 December 2018 © The Author(s) 2018

Abstract
Purpose Primary intradural spinal neoplasms account for a small proportion of central nervous system tumors. The primary treatment for these tumors consists of maximal safe resection and preservation of neurologic function. Gross total resection, which is associated with the lowest rate of tumor recurrence and longer progression-free survival for most histologies, can be difficult to achieve. Currently, the use of 5-aminolevulinic acid (5-ALA) which takes advantage of Protoporphyrin IX (PpIX) fluorescence, is a well-established technique for improving resection of malignant cerebral gliomas. This technique is being increasingly applied to other cerebral neoplasms, and multiple studies have attempted to evaluate the utility of 5-ALA-aided resection of spinal neoplasms.

Methods The authors reviewed the existing literature on the use of 5-ALA and PpIX fluorescence as an aid to resection of primary and secondary spinal neoplasms by searching the PUBMED and EMBASE database for records up to March 2018. Data was abstracted from all studies describing spinal neurosurgical uses in the English language.

Results In the reviewed studies, the most useful fluorescence was observed in meningiomas, ependymomas, drop metastases from cerebral gliomas, and hemangiopericytomas of the spine, which is consistent with applications in cerebral neoplasms.

Conclusions The available literature is significantly limited by a lack of standardized methods for measurement and quantification of 5-ALA fluorescence. The results of the reviewed studies should guide future development of rational trial protocols for the use of 5-ALA guided resection in spinal neoplasms.

Keywords 5-Aminolevulinic acid · Spinal neoplasm · Fluorescence guided resection · Protoporphyrin IX

Background
Primary intradural spinal neoplasms account for a small proportion of central nervous system (CNS) tumors. The combined incidence of malignant and non-malignant primary spinal tumors in the United States is only 0.97 per 100,000 persons [1]. In a review of the National Cancer Database, primary tumors of the spinal cord, meninges, or cauda equina represented just 4.5% of all patients diagnosed with primary tumors of the CNS [2]. The majority of these tumors are benign (48.6–62.4%); the remainder are either borderline but non-malignant (12.8–15.6%) or malignant (22-38.6%) [1, 2]. Histologically, meningiomas are the most common primary spinal tumors, followed by nerve sheath tumors, ependymomas, and astrocytomas [1–3]. Gross total resection is associated with the lowest rate of tumor recurrence and longer progression-free survival for most histologies. Currently, the primary treatment for these tumors consists of maximal safe resection with preservation of neurologic function [4–10]. Unfortunately, subtotal resection is not uncommon particularly with intramedullary ependymoma (19–44%) and astrocytoma (60–94%), in part because of premature termination of surgery for deterioration in intraoperative neurophysiological monitoring, residual tumor not visible with conventional surgical techniques, an indistinct plane of resection, or diffuse infiltration of the spinal cord [3–6, 9, 11–15].

Fluorescence-guided resection of malignant cerebral gliomas utilizing 5-aminolevulinic acid (5-ALA) and
protoporphyrin IX (PpIX) accumulation in tumors has become a well-established technique to facilitate greater extent of resection resulting in improved progression free survival [16–23]. 5-ALA has also been used with varying success in other cerebral neoplasms, such as meningiomas, medulloblastomas, ependymomas, and carcinoma metastases [24–29]. The utility of 5-ALA guided resection of spinal neoplasms has not been determined, but there is a growing body of literature describing its use. The purpose of this review is to identify and summarize the published reports on the use of 5-ALA in spinal neoplasms and define the histopathologic entities that are potential candidates for 5-ALA guided resection.

Methods

Search strategy and data extraction

A literature search of the PUBMED and EMBASE databases was conducted using the keywords “5-aminolevulinic acid,” “spinal,” “spinal tumor,” and “fluorescence,”. See Supplement 1 for search strings. All identified records from January 1, 1964 to March 1, 2018 were reviewed. Records were included if they described the use of 5-ALA-aided resection for spinal neoplasms in humans. Records were excluded if they described the use of 5-ALA for resection of cranial tumors, for non-neurosurgical uses, or if a fluorophore other than 5-ALA was used. Publications written primarily in languages other than English were also excluded. No records were found to be duplicates.

Records were reviewed, and data were extracted regarding basic patient demographics, spinal segment of the tumor, tumor location (e.g. extradural [ED]; intradural, extramedullary [ID-EM]; intradural, intramedullary [IM]), histology, World Health Organization (WHO) Grade, and presence or absence of fluorescence and its characteristics. Because of the lack of standardization in quantifying fluorescence any reported degree of fluorescence was considered a positive result and any further characterization was noted. Data for individual patients were provided in all records.

Results

Study selection and patient characteristics

A total of 202 records were identified through our initial database search. De-duplication left 192 unique records. Titles and abstracts of these records were screened and 182 records were excluded as not relevant to the review yielding 10 records. Full texts of these records were reviewed and 2 articles written in non-English languages were excluded. The remaining 8 articles, which are the subject of this review, are summarized in Tables 1, 2 and 3 [3, 13, 22, 30–34]. A detailed flow chart of study identification and selection is presented in Fig. 1. For a full table of all abstracted data see Supplement 2. Screening of the references of included studies did not yield any additional articles for inclusion.

There were 5 case reports and 3 prospective case series in the 10 articles reviewed. The literature described 91 patients (53 female, 44 male, average age 44.5 years) with 97 tumors; when duplicate patients are excluded, there were 94 unique tumors [3, 13, 22, 30–34]. In the reports where 5-ALA dosing information was provided, patients received 20 mg/kg orally 2–3 h prior to induction of anesthesia in all cases except those reported by Shimizu et al. [31], who administered 1 gm of 5-ALA orally 2 h prior to induction. Fluorescence was usually visualized using a neurosurgical microscope with integrated 5-ALA-PpIX fluorescence visualization capability that allows for switching between white light and blue excitation light for fluorescence visualization; Shimizu et al. [31] used an external semiconductor laser excitation source. ID-EM tumors made up the majority of tumors (n = 52, 55.3%), followed by IM (n = 36, 38.3%), and ED (n = 6, 6.4%) tumors. Meningiomas (n = 21, 22.34%) were the most common histology followed by intramedullary ependymoma (n = 22 23.41%), neurinoma (n = 14, 23.41%), and neurinoma (n = 14, 23.41%).

Table 1 List of included studies

| Publication       | Tumors included | ALA dose      | Light source                      | Fluorescence positivity |
|-------------------|-----------------|---------------|----------------------------------|-------------------------|
| Shimizu et al. [31] | 1               | 1 gram        | Laser device                     | 1/1 (100%)              |
| Ewelt et al. [32]  | 1               | 20 mg/kg BW   | Violet-blue light microscope     | 1/1 (100%)              |
| Rapp et al. [22]  | 2               | Not reported  | Not reported                     | 2/2 (100%)              |
| Inoue et al. [13]  | 10              | 20 mg/kg BW   | Violet-blue light microscope     | 7/9 (77%)               |
| Muroi et al. [30]  | 1               | 20 mg/kg BW   | Violet-blue light microscope     | 1/1 (100%)              |
| Eicker et al. [33] | 26              | 20 mg/kg BW   | Violet-blue light microscope     | 12/26 (46%)             |
| Millesi et al. [3] | 55              | 20 mg/kg BW   | Violet-blue light microscope     | 29/55                   |
| Krause Molle et al. [34] | 1       | 20 mg/kg BW   | Violet-blue light microscope     | 1/1 (100%)              |

a1 patient not administered 5-ALA
Table 2  List of included studies with histology

| Publication                | Tumors included                                      | Histology (grade)                  | Fluorescence positivity |
|----------------------------|------------------------------------------------------|-----------------------------------|-------------------------|
| Shimizu et al. [31]        | 1                                                    | Ependymoma (WHO II) (n = 1)       | 1/1 (100%)              |
| Ewelt et al. [32]          | 1                                                    | Anaplastic astrocytoma (WHO III) (n = 1) | 1/1 (100%)              |
| Rapp et al. [22]           | 2                                                    | Epidural metastasis (Anaplastic oligoastrocytoma) (n = 1) | 1/1 (100%)              |
|                            |                                                     | Drop metastasis (Glioblastoma) (n = 1) | 1/1 (100%)              |
| Inoue et al. [13]          | 10                                                   | Ependymoma (WHO II) (n = 9)       | 6/8 (75%)
|                            |                                                     | Anaplastic ependymoma (WHO III) (n = 1) | 1/1 (100%)              |
| Muroi et al. [30]          | 1                                                    | Meningothelial meningoma (WHO I) (n = 1) | 1/1 (100%)              |
| Eicker et al. [33]         | 26                                                   | Meningioma (n = 8)                | 7/8 (75%)               |
|                            |                                                     | Meningothelial (WHO I) (n = 6)    | 6/6 (100%)              |
|                            |                                                     | Psammomatous (WHO I) (n = 1)      | 0/1 (0%)                |
|                            |                                                     | Transitional (WHO I) (n = 1)      | 1/1 (100%)              |
|                            |                                                     | Neurinoma/neurofibroma (n = 7)    | 0/7 (0%)                |
|                            |                                                     | Neurinoma (WHO I) (n = 1)         | 0/1 (0%)                |
|                            |                                                     | Neurofibroma (WHO I) (n = 1)      | 0/1 (0%)                |
|                            |                                                     | Gliomas (n = 4)                   | 4/4 (100%)              |
|                            |                                                     | Anaplastic astrocytoma (WHO III) (n = 1)b | 1/1 (100%)              |
|                            |                                                     | Glioblastoma (WHO IV) (n = 1)     | 1/1 (100%)              |
|                            |                                                     | Drop metastasis (Glioblastoma) (n = 1)c | 1/1 (100%)              |
|                            |                                                     | Epidural metastasis (Anaplastic Astrocytoma) (n = 1)d | 1/1 (100%)              |
|                            | Other histologies (n = 7)                           | 1/7 (14%)                         |
|                            |                                                     | Myxopapillary ependymoma (WHO I) (n = 2) | 1/2 (50%)               |
|                            |                                                     | Medulloblastoma (WHO IV) (n = 1)   | 0/1 (0%)                |
|                            |                                                     | Metastatic choroid plexus papilloma (WHO I) (n = 1) | 0/1 (0%)                |
|                            |                                                     | Epidermoid cyst (n = 1)           | 0/1 (0%)                |
|                            |                                                     | Intramedullary lipoma (n = 1)     | 0/1 (0%)                |
|                            |                                                     | Demyelinating disease (n = 1)     | 0/1 (0%)                |
| Millesi et al. [3]         | 55                                                   | Meningioma (n = 12)               | 12/12 (100%)            |
|                            |                                                     | Meningothelial (WHO I) (n = 7)    | 7/7 (100%)              |
|                            |                                                     | Transitional (WHO I) (n = 1)      | 1/1 (100%)              |
|                            |                                                     | Psammomatous (WHO I) (n = 3)      | 3/3 (100%)              |
|                            |                                                     | NOS (WHO I) (n = 1)               | 1/1 (100%)              |
|                            |                                                     | Hemangiopericytoma (WHO II) (n = 2) | 2/2 (100%)              |
|                            |                                                     | Anaplastic Hemangiopericytoma (WHO III) (n = 1) | 1/1 (100%)              |
|                            |                                                     | Chordoma (n = 2)                  | 0/2 (0%)                |
|                            |                                                     | Ependymoma (n = 11)               | 11/11 (100%)            |
|                            |                                                     | Ependymoma (WHO II) (n = 10)      | 10/10 (100%)            |
|                            |                                                     | Anaplastic (WHO III) (n = 1)      | 1/1 (100%)              |
|                            |                                                     | Myxopapillary ependymoma (WHO I) (n = 1) | 1/1 (100%)              |
|                            |                                                     | Neurinoma (WHO I) (n = 8)         | 0/8 (0%)                |
|                            |                                                     | Glioma (n = 3)                    | 0/3 (0%)                |
|                            |                                                     | Pilocytic astrocytoma (WHO I) (n = 1) | 0/1 (0%)                |
|                            |                                                     | Diffuse astrocytoma (WHO II) (n = 1) | 0/1 (0%)                |
|                            |                                                     | Anaplastic mixed oligoastrocytoma (WHO III) (n = 1) | 0/1 (0%)                |
|                            |                                                     | Hemangioblastoma (n = 2)          | 0/2 (0%)                |
|                            |                                                     | Paraganglioma (n = 1)             | 0/1 (0%)                |
|                            |                                                     | Ganglioglioma (n = 1)             | 0/1 (0%)                |
|                            |                                                     | Amelanotic melanocytoma (n = 1)  | 0/1 (0%)                |
|                            |                                                     | Metastasis (n = 7)                | 2/7 (28%)               |
|                            |                                                     | Giant cell tumor of bone (n = 1)  | 0/1 (0%)                |
|                            |                                                     | Lipoma (n = 1)                    | 0/1 (0%)                |
|                            |                                                     | Malignant peripheral nerve sheath tumor (n = 1) | 0/1 (0%)                |
| Krause Molle et al. [34]   | 1                                                    | Leptomeningeal Spread of Anaplastic Astrocytoma (n = 1) | 1/1 (100%)              |

a 1 patient not administered 5-ALA
b Previously reported in Ewelt et al. [32]
c Previously reported in Rapp et al. [22]
5-ALA in the resection of a spinal meningioma in 2012. Muroi et al. [30] published the first report of the use of 5-ALA and PpIX fluorescence in the resection of 21 meningiomas [3, 30, 33]. All meningiomas resected were WHO grade I. Meningothelial meningiomas represented the most frequent histology (n = 11, 52.38%), followed by transitional (n = 4, 19.05%) and psammomatous (n = 4, 19.05%) meningiomas, metaplastic (n = 1, 4.76%), and 1 case reported as meningioma NOS (4.76%). Of the cases reported, all but one (95%) demonstrated positive PpIX fluorescence. This fluorescence-positive remnant demonstrated identical histology to the bulk of the tumor. In this case, 5-ALA fluorescence selectively marked tumor tissue, enabling a more complete resection, and the patient was recurrence free on short-term, 1-year follow-up imaging [30].

Eicker et al. [33] published the largest series of spinal intradural tumors in 2013, which included 8 meningiomas. Fluorescence-guided resection revealed 3 meningothelial, 3 transitional, 1 psammomatous, and 1 metaplastic tumors; two tumors (1 meningothelial and 1 transitional) were recurrences. All tumors where WHO grade I. All tumors, except the psammomatous tumor, demonstrated positive fluorescence. This non-fluorescence was attributed to a delay (approximately 7 h) between the administration of 5-ALA and surgery. Alternatively, differences in ferrochelatase activity in meningioma cell lines that can reduce the accumulation of PpIX may have been responsible for the lack of fluorescence visualization [35]. Importantly, in the two cases of recurrent tumors, the authors reported that fluorescence was useful in distinguishing between areas of tumor and scar, with no fluorescence-negative tissue samples positive for tumor. In addition, they identified residual fluorescent tumor after apparent complete resection under white light in these same cases [33].

Millesi et al. [3] published the largest series of spinal tumors in which 5-ALA fluorescence was used. After presumed gross total tumor resection under white-light microcopy, a final inspection of the surgical cavity was performed to assess for residual fluorescence. In their series of 55 tumors, they reported 12 meningiomas (7 meningothelial, 3 psammomatous, 1 transitional, and 1 meningioma NOS), all WHO grade I. All tumors exhibited strong fluorescence; 10 (83.33%) tumors demonstrated homogeneous fluorescence and 2 (1 meningothelial and 1 psammomatous) demonstrated inhomogeneous fluorescence [3]. Using a MIB-1 antibody kit to evaluate proliferation rate in fluorescence-negative and -positive samples from the inhomogeneously fluorescing tumors, Millesi et al. observed a higher mean proliferation rate in the fluorescence positive areas which is consistent with data from cerebral gliomas [3, 13, 36, 37].

Together, these authors demonstrate the utility of 5-ALA fluorescence in the resection of spinal meningiomas. All spinal meningiomas in these studies were reported to have a gross total resection or a resection of at least Simpson grade II with 5-ALA fluorescence facilitating more complete resection. These data are in agreement with recent publications

| Histology                  | Fluorescence positivity |
|----------------------------|-------------------------|
| Meningioma (n = 21)        | 20/21 (95%)             |
| Meningothelial (WHO I) (n = 14) | 14/14 (100%)          |
| Psammomatous (WHO I) (n = 4) | 3/4 (75%)              |
| Transitional (WHO I) (n = 2) | 2/2 (100%)            |
| NOS (WHO I) (n = 1)        | 1/1 (100%)              |
| Hemangiopericytoma (n = 3) | 3/3 (100%)             |
| Hemangiopericytoma (WHO II) (n = 2) | 2/2 (100%)        |
| Anaplastic hemangiopericytoma (n = 1) | 1/1 (100%)       |
| Ependymoma (n = 22)        | 19/21^4                |
| Ependymoma (WHO II) (n = 20) | 17/19 (89%)            |
| Anaplastic ependymoma (WHO III) (n = 2) | 2/2 (100%)        |
| Myxopapillary ependymoma (n = 3) | 2/3 (66%)             |
| Glioma (n = 7)             | 7/7 (100%)              |
| Pilocytic astrocytoma (n = 1) | 0/1 (0%)               |
| Diffuse astrocytoma (n = 1) | 0/1 (0%)               |
| Anaplastic astrocytoma (WHO III) (n = 3) | 3/3 (100%)      |
| Anaplastic oligoastrocytoma (WHO III) (n = 1) | 1/1 (100%)      |
| Glioblastoma (n = 1)       | 1/1 (100%)              |
| Neurinoma (n = 15)         | 0/15 (0%)               |
| Metastases (n = 12)        | 6/12 (50%)              |
| Medulloblastoma (n = 1)    | 0/1 (0%)                |
| Chordoma (n = 2)           | 0/2 (0%)                |
| Other histologies (n = 11) | 0/11 (0%)               |

^1 of the 22 patients with ependymoma did not receive 5-ALA
describing the use of 5-ALA in intracranial meningiomas [24, 29]. The ability to visualize residual tumor not identifiable under white light visualization is extremely beneficial as Simpson grade I-III resections are associated with symptom resolution and low recurrence rates [7, 8, 10, 29, 30, 33, 38]. Additionally, this ability to visualize tumor may allow for less aggressive surgery; the ability to target fluorescence tumor and visualize tumor as it arises from the dura, including any potential dural invasion, could facilitate more targeted resection to achieve a Simpson grade I-III result. However, this must be balanced with the potential for intratumoral heterogeneity and areas of non-fluorescing tumor that may mislead the surgeon.

Ependymoma

Four studies reported the use of 5-ALA and PpIX fluorescence in the resection of 24 ependymomas [3, 13, 31, 33]. Intramedullary ependymomas represented the majority of the reported tumors (n = 22), of which 20 (91%) were ependymoma (WHO grade II) and 2 (9%) were anaplastic ependymoma (WHO grade III). Three myxopapillary ependymomas (WHO grade I) were reported as well. Eighty-seven percent of tumors exhibited positive fluorescence, with 2/2 (100%) of anaplastic intramedullary ependymomas (WHO grade III), 17/19 (89%) of intramedullary ependymomas (WHO grade II), and 2/3 (67%) of myxopapillary ependymomas (WHO grade I) exhibiting PpIX positivity [3, 13, 31, 33]. One patient with Inoue et al.’s study did not receive 5-ALA.

Shimizu et al. [31] reported the first use of 5-ALA in the resection of a cervical intramedullary ependymoma (WHO I) in 2006. The tumor exhibited strong fluorescence, aiding in en bloc resection of the tumor. They achieved an apparent gross total resection under white light visualization and under conventional fluorescence visualization no residual tumor was visible. Further analysis of the fluorescence spectrum of the resection bed revealed peaks consistent with PpIX at the site of tumor attachment to the anterior raphe, suggesting residual foci of tumor. They proceeded with additional resection and final fluorescence examination of the tumor bed demonstrated no emission peaks, confirming complete removal of the tumor [31].

Inoue et al. [13] published the first series of intramedullary ependymomas resected utilizing 5-ALA fluorescence-guided resection in 2012. They reported 10 consecutive patients with intramedullary ependymoma who underwent resection from June 2006 to December 2010. One patient
enrolled in the study refused to receive 5-ALA. Fluorescence-guided resection was performed, and histological analysis revealed 9 ependymomas (WHO grade II) and 1 anaplastic ependymoma (WHO grade III). Of the 9 patients who received 5-ALA, 7 (77%) demonstrated strong positive tumor fluorescence. Of the fluorescence-positive tumors, 4/7 (57%) exhibited uniform fluorescence and 3/7 (43%) demonstrated heterogeneous fluorescence. The authors achieved gross total resection in 8 of 10 (80%) of patients. All of the patients who demonstrated positive fluorescence had complete resection of fluorescenting tissue and demonstrated complete resection of tumor on follow-up; of the two fluorescence-negative tumors and the tumor in the patient who did not receive 5-ALA, total resection was accomplished in only one case. Inoue et al. [13] reported that 5-ALA fluorescence enabled more clear visualization of dissection planes and was particularly useful in delineating the ventral, cranial, and caudal margins of the tumors. All tumor samples taken from fluorescence-positive areas contained tumor. Additionally, cell proliferation indices were assessed using the MIB-1 antibody and demonstrated significantly higher proliferation indices for fluorescence-positive areas of tumor compared with negative areas [13].

Eicker et al. [33] reported on the resection of 2 myxopapillary ependymomas (WHO grade I). Only 1 of 2 ependymomas exhibited positive fluorescence, and the authors made no comment on the character of the fluorescence. They noted that, when present, fluorescence facilitated complete resection [33].

Millesi et al. [3] reported on the resection of 12 ependymomas. Ten were intramedullary ependymoma (WHO grade II), 1 was intramedullary anaplastic ependymoma (WHO grade III), and 1 was myxopapillary ependymoma (WHO grade I). For resections of these tumors, the authors utilized principles of fluorescence-guided resection to facilitate complete removal of tumor. They observed strong positive fluorescence in 10/12 (83%) and weak fluorescence in 1 ependymoma (WHO grade II). Fluorescence was homogeneous in 5/12 (42%) of tumors. Similar to the previous reports, the authors were able to identify residual fluorescenting foci in 4 intramedullary ependymomas that were positive for tumor upon resection. Gross total resection was achieved in 9 of 12 (75%) ependymomas. An infiltrative growth pattern, absence of a clear cleavage plane, and neuromonitoring changes were cited as the primary reasons for incomplete resection in their series overall [3].

As with the reported cases of spinal meningioma resected utilizing 5-ALA fluorescence, these reports demonstrate that 5-ALA fluorescence-guided resection of spinal ependymomas can facilitate more complete resection when the tumor exhibits positive fluorescence. When extent of resection was reported, gross total resection was achieved in 17/22 (77%) of cases and subtotal resection was reported in 5/22 (23%) of cases which is similar to prior reports [3, 13, 39, 40]. Given that extent of resection, along with histology, is the most important prognostic factor in post-surgical outcome and progression-free survival, 5-ALA guided resection of spinal ependymomas is a reliable and clinically significant adjunct to surgery in these patients [14, 38, 39, 41–43].

**Drop metastases of cerebral neoplasms**

Three studies reported the use of 5-ALA fluorescence in the resection of 6 drop metastases from cerebral neoplasms [3, 22, 33]. Three lesions were drop metastases of cerebral glioblastomas (WHO grade IV). 1 was a medulloblastoma (WHO grade IV) metastasis, 1 was a choroid plexus papilloma metastasis (WHO grade I), and 1 was pineal gland papillary tumor (WHO grade II–III). All of the glioblastoma metastases and the pineal gland papillary tumor metastasis exhibited positive fluorescence, which the authors found it useful in aiding their resection of these tumors because it distinguished between tumor and normal tissue well. The medulloblastoma metastasis and the choroid plexus papilloma metastasis did not demonstrate fluorescence. Although, reports of spinal drop metastases of malignant cerebral gliomas are rare, the significant progress made in survival times can be assumed to lead to an increased frequency of these metastases [44, 45]. 5-ALA guided resection has proven to be beneficial in cerebral malignant gliomas and appears to be a feasible approach in spinal metastases, but it remains unclear from the available data whether this approach will provide clinical benefit to these patients. There is also insufficient data to determine whether 5-ALA-guided resection of other histologic types of drop metastases will prove beneficial, although data from cerebral medulloblastoma suggests varying fluorescence in this entity may limit the utility [25, 28].

**Other histologies with positive fluorescence**

A very small number of other histologies were reported to have positive fluorescence, including 3 hemangiopericytomas (2 WHO grade II and 1 anaplastic WHO grade III), 1 intramedullary anaplastic astrocytoma (WHO grade III), 1 leptomeningeal metastasis of intramedullary anaplastic astrocytoma (WHO grade III), 1 ganglioglioma (WHO grade I), and 1 epidural metastasis of a cerebral anaplastic oligoastrocytoma (WHO grade III) [3, 22, 32, 34]. 5-ALA fluorescence may be useful in the resection of these entities although more data are needed. The application of 5-ALA in intramedullary astrocytoma is not likely to provide significant benefit despite the evidence that some tumors may exhibit positive fluorescence. In contrast to cerebral astrocytoma, exquisitely eloquent spinal cord tissue very intimately surrounds intramedullary tumors and is infiltrated...
by tumor cells, increasing the risk associated with resecting fluorescent tissue that may contain functional, normal tissue. Additionally, an increased extent of resection has not been shown to provide significant benefit to these patients [9].

Fluorescence-negative tumors

In contrast to the above, none of the other histologies—which included 14 neurinomas, 5 epidural carcinoma metastases, 3 primary spinal gliomas, and 1 intramedullary carcinoma metastasis exhibited positive fluorescence (see Table 1 for the full list) [3, 33]. Based on the available data, 5-ALA does not appear to be useful for these tumors.

Illustrative case

Inoue et al. [13] described a 25-year-old woman who presented with a 3-month history of back pain and difficulty walking (McCormick grade III). Magnetic resonance imaging revealed a homogeneously enhancing intramedullary T3-5 tumor with central canal expansion observed from T6 to T8 (Fig. 2). After a discussion of the risks and benefits of surgical intervention, the decision was made to perform surgical resection of the lesion. 5-ALA was administered 2 h prior to induction, and the tumor was exposed through a standard, posterior midline approach. Excitation light demonstrated vivid, heterogeneous red fluorescence of the tumor (Fig. 3). The tumor was resected; although the tumor appeared to be contiguous with the cyst wall at the cranial, caudal, and ventral aspects of the cyst wall however no fluorescence was identified and this tissue was not resected (Fig. 3). Histopathological analysis of fluorescence-positive tissue demonstrated ependymoma (WHO grade II) (Fig. 3). Samples from the cranial and caudal end of the resection bed, which were fluorescence-negative, were negative for tumor cells. Post-operative magnetic resonance imaging confirmed complete resection, the patient demonstrated improvement in her neurologic status, and there was no evidence of recurrence at 24.1 months postoperatively. This case highlights the utility of 5-ALA fluorescence in guiding tumor resection and reducing unnecessary resection of normal tissue which could lead to neurologic deficit [13].

Discussion

Our review of the available literature describing the use of 5-ALA fluorescence during resection of spinal neoplasms found that positive fluorescence was observed most consistently and proved to be most beneficial with meningiomas, ependymomas, drop metastases from malignant cerebral gliomas, and hemangiopericytomas, consistent with what is observed in applications of 5-ALA in cerebral neoplasms [24, 29, 46].

A major limitation of the available literature is that a standardized method for the measurement and quantification of 5-ALA fluorescence has not been established. Because of this, most studies relied on subjective characterization which can introduce significant bias. No study was able to report on the sensitivity or specificity of fluorescence further limiting the conclusions that can be drawn from available data.
Despite this, the theoretical and demonstrated advantages of enhanced tumor visualization make this technique a valuable adjunct to resection, provided the tumor exhibits positive fluorescence. The heterogeneity of the visible fluorescence response within these tumor entities can potentially reduce the utility of 5-ALA-guided resection; however, as has been demonstrated, 5-ALA-induced PpIX fluorescence of tumor tissue can be detected quantitatively [13, 24, 30, 31, 47, 48]. Real-time, quantitative measurement of PpIX fluorescence and other novel techniques such as confocal endomicroscopy during resection of tumors that do not homogenously fluoresce may be able to overcome this limitation [49].

Another limitation of the available reports is the lack of a standardized method of evaluating the preoperative imaging
for characteristics that could predict useful fluorescence during surgery. Future studies should aim to predict whether 5-ALA fluorescence will be useful by assessing preoperative imaging so unnecessary administration of 5-ALA can be avoided. From the above reports, it is likely that suspected neurinomas are poor candidates for the use of 5-ALA.

Lastly, long-term follow-up is missing on the vast majority of patients reported in the literature. Until longer follow-up has been achieved and reported, data on the overall and progression-free survival rates remain incomplete and the benefits of 5-ALA-guided resection uncertain.

**Conclusion**

In this review, we summarized the available literature describing the use of 5-ALA fluorescence during resection of spinal neoplasms, all of which is Level IV evidence. Positive fluorescence was observed most consistently and proved to be most beneficial to facilitate resection with meningiomas, ependymomas, drop metastases from malignant cerebral gliomas, and hemangiopericytomas, consistent with what is observed in intracranial applications of 5-ALA. These results should guide future development of rational trial protocols for the use of 5-ALA-guided resection of spinal neoplasms.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Duong LM, McCarthy BJ, McLendon RE, Dolecek TA, Kruchko C, Douglas LL, Ajani UA (2012) Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meningiomas, and cauda equina tumors, United States, 2004–2007. Cancer 118:4220–4227

2. Engelhard HH, Villano JL, Porter KR, Stewart AK, Barua M, Barker FG, Newton HB (2010) Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meningiomas, and cauda equina. J Neurosurg Spine 13:67–77

3. Millesi M, Kiesel B, Hoehrer A, Hainfellner JA, Novak K, Martinez-Moreno M, Wolsberger S, Knop E, Widhalm G (2014) Analysis of 5-aminolevulinic acid–induced fluorescence in 55 different spinal tumors. Neurosurg Focus 36:E11

4. Raco A, Esposito V, Lenzi I, Pieciriili M, Delfini R, Cantore G (2005) Long-term follow-up of intramedullary spinal cord tumors: a series of 202 cases. Neurosurgery 56:972–981. discussion 972–81

5. Ottenhausen M, Krieg SM, Meyer B, Ringel F (2015) Functional preoperative and intraoperative mapping and monitoring: increasing safety and efficacy in glioma surgery. Neurosurg Focus 38:E3

6. Bansal S, Ailawadhi P, Suri A et al (2013) Ten years’ experience in the management of spinal intramedullary tumors in a single institution. J Clin Neurosci 20:292–298

7. Yoon SH, Chung CK, Jahng TA (2007) Surgical outcome of spinal canal meningiomas. J Korean Neurosurg Soc 42:300–304

8. Sandalcioglu IE, Hunold A, Muller O, Bassiouni H, Stolke D, Asgari S (2008) Spinal meningiomas: critical review of 131 surgically treated patients. Eur Spine J 17:1035–1041

9. Benes V, Barua P, Benes V, Suchomel P (2009) Prognostic factors in intramedullary astrocytomas: a literature review. Eur Spine J 18:1397–1422

10. Ravindra VM, Schmidt MH (2016) Management of spinal meningiomas. Neurosurg Clin N Am 27:195–205

11. Juthani RG, Bilsky MH, Vogelbaum MA (2015) Current management and treatment modalities for intramedullary spinal cord tumors. Curr Treat Options Oncol 16:39

12. Tobin MK, Geraghty JR, Engelhard HH, Linninger AA, Mehta AI (2015) Intramedullary spinal cord tumors: a review of current and future treatment strategies. Neurosurg Focus 39:E14–E24

13. Inoue T, Endo T, Nagamatsu K, Watanabe M, Tominaga T (2013) 5-aminolevulinic acid fluorescence-guided resection of intramedullary ependymoma: report of 9 cases. Neurosurgery 72:ons159–168. discussion ons168

14. Wostrack M, Ringel F, Eicker SO et al (2018) Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival. J Neurosurg Spine 28:654–662

15. Garcés-Ambrossi GL, McGirt MJ, Mehta VA, Scibubba DM, Witham TF, Bydon A, Wolinsky J-P, Jallo GI, Gokaslan ZL (2009) Factors associated with progression-free survival and long-term neurological outcome after resection of intramedullary spinal cord tumors: analysis of 101 consecutive cases. J Neurosurg Spine 11:591–599

16. Hefti M, von Campe G, Moschopoulos M, Siegner A, Looser H, Landolt H (2008) 5-Aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institution. Swiss Med Wkly 138:180–185

17. Hadjipanayis CG, Widhalm G, Stummer W (2015) What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery 77:663–673

18. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93:1003–1013

19. Stummer W, Kamp MA (2009) The importance of surgical resection in malignant glioma. Curr Opin Neurol 22:645–649

20. Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, Goetz AE, Kiefmann R, Reulen HJ (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42:518–525. discussion 525–526

21. Pichlmieier U, Bink A, Schackert G, Stummer W (2008) Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 10:1025–1034

22. Rapp M, Klingenhofer M, Felsberg J, Steiger HJ, Stummer W, Sabel M (2012) Fluorescence-guided resection of spinal metastases of malignant glioma: report of 2 cases. J Neurol Surg A Cent Eur Neurosurg 73:103–105

23. Stummer W, Pichlmieier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401
24. Motekallemi A, Jeltema HR, Metzemaekers JDM, van Dam GM, Crane LMA, Groen RJM (2015) The current status of 5-ALA fluorescence-guided resection of intracranial meningiomas—a critical review. Neurosurg Rev 38:619–628
25. Preuß M, Renner C, Krupp W et al (2013) The use of 5-aminolevulinic acid fluorescence guidance in resection of pediatric brain tumors. Childs Nerv Syst 29:1263–1267
26. Kamp MA, Grosser P, Felsberg J, Slotty PJ, Steiger HJ, Reifenberger G, Sabel M (2012) 5-Aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study. Acta Neurochir 154:223–228
27. Kamp MA, Fischer I, Bühner J, Turowski B, Cornelius JF, Steiger H-J, Rapp M, Slotty PJ, Sabel M (2016) 5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression. Oncotarget 7:66776–66789
28. Stummer W, Rodrigues F, Schucht P et al (2014) Predicting the “usefulness” of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors: a European survey. Acta Neurochir 156:2315–2324
29. Millesi M, Kiesel B, Mischkulnig M, Martinez-Moreno M, Wöhrer A, Wolfensberger S, Knosp E, Widhalm G (2016) Analysis of the surgical benefits of 5-ALA—induced fluorescence in intracranial meningiomas: experience in 204 meningiomas. J Neurosurg 125:1408–1419
30. Muroi C, Fandino J, Coluccia D, Berkmann S, Fathi A-R, Landolt HM (2013) 5-Aminolevulinic acid fluorescence-guided surgery for spinal meningioma. World Neurosurg 80:223.e1–223.e3
31. Shimizu S, Utsuki S, Sato K, Oka H, Fuji K, Mii K (2006) Photodynamic diagnosis in surgery for spinal ependymoma: Case illustration. J Neurosurg Spine 5:380
32. Ewelt C, Stummer W, Klink B, Felsberg J, Steiger HJ, Sabel M (2010) Corpectomy as final treatment option for diffuse intramedullary malignant glioma using 5-ALA fluorescence-guided resection. Clin Neurol Neurosurg 112:357–361
33. Eicker SO, Floeth FW, Kamp M, Steiger HJ, Hänggi D (2013) The impact of fluorescence guidance on spinal intradural tumour surgery. Eur Spine J 22:1394–1401
34. Krause Molle Z, Gierka K, Turowski B, Steiger HJ, Cornelius JF, Rapp M, Sabel M, Kamp MA (2018) 5-ALA—induced fluorescence in leptomeningeal dissemination of spinal malignant glioma. World Neurosurg 110:345–348
35. Hefzi M, Holenstein F, Albert I, Looser H, Luginbuehl V (2011) Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO i meningioma cells corresponds to ferrochelatase activity. Photochem Photobiol 87:235–241
36. Kiesel B, Mischkulnig M, Woehrer A et al (2017) Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas. J Neurosurg 1–13
37. Widhalm G, Wolfensberger S, Minchev G, Woehrer A, Krssak M, Czech T, Prayer D, Asenbaum S, Hainfellner JA, Knosp E (2010) 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 116:1545–1552
38. Ottenhausen M, Ntoulias G, Bodhinayake I, Ruppert F-H, Schreiber S, Försschler A, Boockvar JA, Jödicke A (2018) Intramedullary spinal tumors in adults—update on management and outcome. Neurosurg Rev. https://doi.org/10.1007/s10143-018-0957-x
39. Karikari IO, Nimjee SM, Hodges TR et al (2011) Impact of tumor histology on resectability and neurological outcome in primary intramedullary spinal cord tumors: a single-center experience with 102 patients. Neurosurgery 68:188–197; discussion 197
40. Boström A, Kanther N-C, Grote A, Boström J (2014) Management and outcome in adult intramedullary spinal cord tumours: a 20-year single institution experience. BMC Res Notes 7:908
41. Klekamp J (2015) Spinal ependymomas. Part 1: intramedullary ependymomas. Neurosurg Focus 39:E6
42. Klekamp J (2015) Spinal ependymomas. Part 2: ependymomas of the filum terminale. Neurosurg Focus 39:E7
43. Lee S-H, Chung CK, Kim CH, Yoon SH, Hyun S-J, Kim K-J, Kim E-S, Eoh W, Kim H-J (2013) Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group. Neuro Oncol 15:921–929
44. Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124:977–988
45. Hübner F, Braun V, Richter HP (2001) Case reports of symptomatic metastases in four patients with primary intracranial gliomas. Acta Neurochir 143:25–29
46. Ferraro N, Barbarie A, Albert TR, Berchmans E, Shah AH, Bregy A, Ivan ME, Brown T, Komotar RJ (2016) The role of 5-aminolevulinic acid in brain tumor surgery: a systematic review. Neurosurg Rev 39:545–555
47. Valdés PA, Jacobs V, Harris BT, Wilson BC, Leblond F, Paulsen KD, Roberts DW (2015) Quantitative fluorescence using 5-aminolevulinic acid-induced protoporphyrin IX biomarker as a surgical adjunct in low-grade glioma surgery. J Neurosurg 123:773–780
48. Li Y, Rey-Dios R, Roberts DW, Valdés PA, Cohen-Gadol AA (2014) Intraoperative fluorescence-guided resection of high-grade gliomas: a comparison of the present techniques and evolution of future strategies. World Neurosurg 82:175–185
49. Belykh E, Martirosyan NL, Yagmurlu K, Miller EJ, Eschbacher JM, Izadyazdanabadi M, Bardonova LA, Byvaltsev VA, Nakaji P, Preul MC (2016) Intraoperative fluorescence imaging for personalized brain tumor resection: current state and future directions. Front Surg 3:55